Sinopharm Tech Holdings Limited provides earnings guidance for the year ended 30 June 2023. The Group is expected to record the loss attributable to equity holders of the Company for the year ended 30 June 2023 to decrease in the range between 80% and 90%, as compared with the loss attributable to equity holders of the Company of approximately HKD 88.0 million for the year ended 30 June 2022. The significant decrease in loss was mainly attributable to, among other things, (i) gain on disposal of locked-up shares related to profit guarantee; (ii) gain on settlement of loans by shares issued; (iii) less impairment losses on goodwill; and (iv) the company having strengthened its efforts in cost control, resulting in less administrative and operating expenses.
Sinopharm Tech Holdings Limited
Equities
8156
KYG2159V1418
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1 HKD | +7.53% | 0.00% | -24.24% |
Feb. 29 | Sinopharm Tech Holdings Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 | CI |
2023 | Sinopharm Tech Holdings Limited Announces Management Changes | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-24.24% | 2.35M | |
-2.31% | 187B | |
-3.20% | 106B | |
-5.04% | 66.9B | |
+0.20% | 49.45B | |
+17.29% | 48B | |
+4.06% | 40.84B | |
+2.07% | 26.48B | |
+2.36% | 26.25B | |
+12.96% | 24.62B |
- Stock Market
- Equities
- 8156 Stock
- News Sinopharm Tech Holdings Limited
- Sinopharm Tech Holdings Limited Provides Earnings Guidance for the Year Ended 30 June 2023